CNS & Neurological Disorders - Drug Targets

Journal Impact Factor: 3.0
Scopus Cite Score: 5.5
Aims and Scope:
CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. CNS & Neurological Disorders - Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of CNS & neurological drug targets. The journal also accepts for publication original research articles, letters, reviews and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.
Read more...
Start Submission Button Icon

Editor-in-Chief:

  • Edoardo Spina Department of Clinical and Experimental Medicine
    University of Messina
    Messina
    Italy

ISSN: 1871-5273 (Print)

eISSN: 1996-3181 (Online)

Special Issues With Active Call for Papers

Submission closes on: Mar 14, 2026
Innovative Therapeutics in Demyelinating CNS- Disorders: Immune Modulation, Antibody Therapy, Kinase Inhibition and Remyeliation Strategies

Demyelinating disorders, particularly multiple sclerosis represent chronic disease characterized by inflammation, demyelination, and neurodegeneration within the central nervous system. This thematic issue will present a comprehensive overview of novel therapeutic advances targeting these processes. In addition to dissecting the roles of innate versus adaptive immunity, antibody therapies, and tyrosine kinase inhibitors, the issue emphasizes emerging remyelination strategies. Recent data—including early intervention with anti-CD20 treatments - underscore the benefits of a “hit hard and early” approach,... see more

Impact Factor: 3.0
Guest Editor(s): Dr. Leonidas Panos
Start Submission
Submission closes on: Feb 07, 2026
Big Data Mining for CNS Diseases Analysis and Treatment: Focusing on Drug Target Discovery

Central nervous system (CNS) diseases, including neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis, represent a major global health challenge. Despite significant research efforts, the complexity and multifactorial nature of these diseases hinder the development of effective treatments. The rise of big data analytics and high-throughput technologies offers new opportunities, particularly in drug target discovery. Multi-omics data from genomics, transcriptomics, proteomics, and other resources (e.g., xQTL, pGWAS, MPRA) have deepened our understanding... see more

Impact Factor: 3.0
Guest Editor(s): Dr. Han Zhijie
Co-Guest Editor(s): Dr. Liu Guiyou,Dr. Cheng Liang,Dr. Tan Yejun
Start Submission
Submission closes on: Dec 31, 2025
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia

More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and reversible. Although individuals carrying the APOE E4 gene have a higher risk of Alzheimer’s disease, lifestyle is the major risk factor for the development of... see more

Impact Factor: 3.0
Guest Editor(s): Dr. Renato Sobral Monteiro-Junior
Start Submission
Submission closes on: Dec 31, 2025
Heart and Brain Axis Targets in CNS Neurological Disorders

Recently, there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system and neurological disorders. The purpose of this special issue is to meticulously explore and elucidate the identification and characterization of therapeutic targets that have the capacity to influence both cardiac... see more

Impact Factor: 3.0
Guest Editor(s): Dr. Melis Olcum
Start Submission
Submission closes on: Dec 31, 2025
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities

The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive overview of the molecular pathways involved in the pathogenesis of neurodegenerative diseases. 2.Highlight Innovations: Showcase recent advancements in therapeutic interventions targeting pathogenic proteins. 3.Foster Collaboration:... see more

Impact Factor: 3.0
Guest Editor(s): Dr. Dr. Nitish Bhatia
Co-Guest Editor(s): Dr. Monu Yadav,Dr. Benu George
Start Submission
Submission closes on: Dec 31, 2025
Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches

Emerging evidence suggests that glial cells may play a pivotal role in neuroanatomical and behavioral changes found in autism spectrum disorder (ASD). Many individuals with ASD experience neuro-immune system abnormalities throughout life, which implicates the potential role of microglia in the pathogenesis of ASD. Dysfunctional astrocytes and oligodendrocytes have been shown to contribute to neurochemical imbalances and modify axonal conduction in ASD. Altogether, it is suggested that alterations in axons and myelin, as well as... see more

Impact Factor: 3.0
Guest Editor(s): Dr. Andrea Stojakovic
Start Submission